Design and selection of DMP 850 and DMP 851: The next generation of cyclic urea HIV protease inhibitors

Chemistry and Biology

Volumn 5, Issue 10, 1998, Pages 597-608

  Rodgers, James D ^a   Lam, Patrick Y S ^a   Johnson, Barry L ^a   Wang, Haisheng ^a   Ko, Soo S ^a   Seitz, Steven P ^a   Trainor, George L ^a   Anderson, Paul S ^a   Klabe, Ronald M ^a   Bacheler, Lee T ^a   Cordova, Beverly ^a   Garber, Sena ^a   Reid, Carol ^a   Wright, Matthew R ^a   Chang, Chong Hwan ^a   Erickson Viitanen, Susan ^a  

^a DUPONT COMPANY   (United States)

Author keywords

AIDS; Cyclic urea; DMP 850; DMP 851; HIV protease

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 13044290051     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(98)90117-X     Document Type: Article

References (30)

1. De Lucca, G.V., Erickson-Viitanen, S., Lam, P.Y.S. (1997). Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule. Drug Discovery Today 2, 6-18.
2. Chrusciel, R.A., Romines, K.R. (1997). Recent developments in HIV protease inhibitor research. Expert Opin. Ther. Pat. 7, 111-121.
3. Kohl, N.E., et.al., & Sigal, I.S. (1988). Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl Acad. Sci. USA 85, 4686-4690.
4. Peng, C., et al., & Chang, N.T. (1989). Role of human immunodeficiency virus type 1 -specific protease in core protein maturation and viral infectivity. J. Virol. 63, 2550-2556.
5. Vacca, J.P. & Condra, J.H. (1997). Drug Discovery Today 2, 261-272.
6. Lam, P.Y.S., et al., & Erickson-Viitanen, S. (1994). Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263, 380-384.
7. Lam, P.Y.S., et al., & Hodge, C.N. (1996). Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J. Med. Chem. 39, 3514-3525.
8. Hodge, C.N., et al., & Erickson-Viitanen, S. (1996). DMP 450: an orally bioavailable cyclic urea inhibitor of the HIV protease. Chem. Biol. 3, 301-314.
9. Bacheler, L.T., Paul, M., Jadhav, P.K., Otto, M., Stone, B. & Miller, J. (1994). Antiviral Chem. Chemother. 5, 111.
10. Zini, R., Barre, J., Defer, G., Jeanniot, J.P., Houin, G., Tillement, J.P. (1985). Protein binding of propisomide. J. Pharm. Sci. 74, 530-533.
11. King, R.W. et al., & Otto, M.J. (1995). Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem. Chemother. 6, 80-88.
12. Rodgers, J.D., et al., & Chang, C.-H. (1996). Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2′ groups. Bioorg. Med. Chem. Lett. 6, 2919-2924.
13. Rodgers, J.D., et al., & Chang, C.-H. (1998). Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2′ groups. Bioorg. Med. Chem. Lett. 8, 715.
14. Jadhav, P.K., et al., & Bacheler, L.T. (1997). Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40, 181-191.
15. Pierce, M., et al., & Emmett, G.C. (1996). Stereoselective synthesis of HIV-1 protease inhibitor DMP 323. J. Org. Chem. 61, 444-450.
16. Erickson-Viitanen, S., et al., & Meek, J.L. (1994). Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. Antimicro. Agents Chemo. 38, 1628-1634.
17. Winslow, D.L., et al., & Otto, M.J. (1995). Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res. Hum. Retroviruses 11, 107-113.
18. Livingston, D.J., et al., & Painter, G.R. (1995), Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172, 1238-1245.
19. Houin, G. (1995). Drug binding and apparent volume of distribution. In Protein Binding and Drug Transport (Tillement, J.P. & Lindendlaub, E., eds.), p213-226, Schatauer, Stuggart.
20. Ho, D.D, et al., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
21. Wei, X., et al., & Shaw, G.M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
22. King, R.W. et al., & Otto, M.J. (1995). Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem. Chemother. 6, 80-88.
23. Condra J.H., et al., & Emini, E.A. (1995), In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
24. Kravcik, S. et al., & Cameron, D.W. (1998). Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection. 5th Conference on Retroviruses and Opportunistic Infections, Feb. 1-5, 1998, Chicago, Il., Abstract 394c.
25. Anton, E.D. et al., & Bacheler, L.T. (1996). Influence of Gag sequences on the replicative capatcity of HIV-1 protease mutants. Fifth Workshop on HIV Drug Resistance, July 3-6, Whistler, Canada, Abstract 19.
26. Rose, R.E. et al., & Lin, P.F. (1996). Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl Acad. Sci. USA 93, 1648-1653.
27. Vacca, J.P., et al., & Huff, J.R. (1994). L735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl Acad. Sci. USA 91, 4096-4100.
28. Kempf, D.J., et al., & Norbeck D.W. (1995). ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl Acad. Sci. USA 92, 2484-2488.
29. Roberts, N.A. (1995). Drug resistant patterns of saquinavir and other HIV protease inhibitors. AIDS 9, S27-S32.
30. Shetty, B.V., Kosa, M.B., Khalil, D.A. & Webber, S. (1996). Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of the HIV type 1 protease. Antimicrobial Agents and Chemo. 40, 110-114.